Chronic Myeloid Leukemia malady

MedlinePlus: Leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, however, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in chronic myeloid leukemia (cml), there are too many of a specific type of white blood cell called a granulocyte. sometimes cml does not cause any symptoms at all. if you have symptoms, they may include: feeling very tired weight loss night sweats fever pain or a feeling of fullness below the ribs on the left side tests that examine the blood and bone marrow diagnose cml. treatments include chemotherapy, radiation therapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, immune therapy, or surgery to remove the spleen. nih: national cancer institute²³

MalaCards: Chronic Myeloid Leukemia, also known as leukemia, chronic myeloid, is related to myeloid leukemia and leukemia. An important gene associated with Chronic Myeloid Leukemia is ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase), and among its related pathways are Natural killer cell mediated cytotoxicity and Jak/Stat Pathway. The drugs isotretinoin and thioguanine and the compounds calcium and lipid have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, lymph node and spleen, and related mouse phenotypes are hematopoietic system and mortality/aging.

Wikipedia: Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a...⁴⁴ more...

OMIM: 608232

Aliases & Descriptions:

chronic myeloid leukemia 6 30 8 23 leukemia, chronic myeloid 30 33 myeloid leukemia, chronic 6 43 cml 6 30 chronic myelogenous leukemia, no icd-o subtype (morphologic abnormality) 6 chronic myeloid leukemia without mention of remission 6 chronic myeloid leukemia in remission (disorder) 6 chronic myeloid leukemia, disease (disorder) 6 chronic myeloid leukemia nos (disorder) 6

chronic myeloid leukemia in remission 6 cml - chronic myelogenous leukemia 6 chronic granulocytic leukemia 30 chronic myelogenous leukemia 30 chronic myeloid leukaemia 6 myeloid leukemia chronic 32 myeloid leukemia 43 cml in remission 6 leukemia 43

Diseases related to chronic myeloid leukemia by text searches and GeneDecks gene sharing:

(show top 50)    (show all 962)

id	Related Disease	Score	Top Affiliating Genes
1	myeloid leukemia	64.2	ZNF673, PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2
2	leukemia	63.5	ZNF673, PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2
3	carcinoma	44.1	ZNF673, PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2
4	chronic lymphocytic leukemia	43.2	SELL, MYB, BLZF1, BIRC5, BCL2, BCL2L1
5	t-cell leukemia	41.5	PIK3CG, RELA, MYC, MYB, RAF1, BLZF1
6	adult t-cell leukemia	39.5	NCAM1, MYC, MYB, BCL2, BCL2L1, BCL6
7	prostatitis	39.2	ZNF673, PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2
8	acute lymphoblastic leukemia	38.4	KIT, KITLG, KIR3DL1, RB1, SELL, MYB
9	acute leukemia	36.7	PIK3CA, NCAM1, KIT, KITLG, PCM1, RB1
10	myelodysplastic syndrome	36.4	PIAS4, PIK3CG, NCAM1, KIT, KITLG, KIR3DL1
11	human t-cell leukemia virus type 1	36.4	PDCD1, RELA, RB1, MYC, MYB, RAN
12	hepatitis	36.2	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
13	neuronitis	36.2	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
14	down syndrome	36.0	RB1, MYC, BCL6, BCR, JAK2, CDC25C
15	leukemia/lymphoma	35.8	PIK3CA, PIK3CG, PDCD1, KITLG, RB1, VEGFA
16	acute myeloid leukemia	35.7	ZNF673, PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2
17	lymphocytic leukemia	35.4	PIK3CD, PIK3CA, PIK3CG, NCAM1, RELA, KIT
18	hodgkin's lymphoma	35.2	PIK3R1, PIK3CG, SELP, BRCA1, BMI1, BLZF1
19	childhood leukemia	35.0	BCL2, BCL2L1, LEP, BAX, CDKN1A, CDKN2B
20	hairy cell leukemia	34.9	BRAF, CD52, CD44, ITGAE, FGF2, IL1A
21	lymphoblastic leukemia	34.8	PIK3CA, PIK3CG, NCAM1, NCOA3, RELA, KIT
22	b-cell lymphomas	34.6	RB1, MYC, BMI1, BLZF1, BIRC5, PARP1
23	megakaryoblastic leukemia	34.5	KIT, KITLG, SELP, VDR, BMP6, MPO
24	acute megakaryoblastic leukemia	34.5	KIT, BMP6, MPO, JAK2, FLT3, IL3
25	prolymphocytic leukemia	34.1	VEGFA, MYC, CDKN1B, CD52, CD19, CD7
26	burkitt's lymphoma	34.0	MYC, MYB, BMI1, BMP6, RASSF1, BIRC5
27	myeloproliferative disorder	34.0	KIT, KITLG, SELP, RAN, KDR, BCR
28	acute lymphoblastic leukemia, childhood	33.8	PARP1, BCL2L1, BCR, BAX, CDK2, CDKN2B
29	t-cell prolymphocytic leukemia	33.6	VEGFA, CDKN1B, CD52, CD19, CD7, CD38
30	acute myelomonocytic leukemia	33.5	MYB, MPO, MECOM, IL3, ANPEP, TNF
31	leukemia/lymphoma, t-cell	33.4	KITLG, RB1, MYC, PARP1, BCL2, UGCG
32	myeloma	33.4	PIK3CA, PIK3R2, PIK3R1, PIK3CG, NCAM1, RELA
33	large granular lymphocyte leukemia	33.3	PIK3CG, BCL2, BCL2L1, BCL2L11, CD52, IL10
34	monocytic leukemia	33.1	SELP, SERPINB2, VEGFA, MYC, BMP6, BIRC5
35	multiple myeloma	33.0	NCAM1, BCL2L1, CD19, CD44, FGFR3, IL6
36	severe congenital neutropenia	32.8	KITLG, BIRC5, LEF1, JAK2, IL3, ELANE
37	chronic myelomonocytic leukemia	32.8	RB1, RAN, BIRC5, MPO, JAK2, CDK6
38	plasma cell leukemia	32.8	NCAM1, BRAF, CDKN2A, CDK4, ITGB1, IRF4
39	acute myeloid leukemia, adult	32.8	NCAM1, KIT, BCL2L1, CDKN2B, CD34, FLT3
40	mastocytosis	32.5	PIK3CD, PIK3CA, PIK3R1, KIT, KITLG, BSPH1
41	breast cancer	32.5	PIK3CA, NCOA3, BRCA1, MYC, BMP6, UBC
42	graft versus host disease	32.4	KIR3DL1, SELL, GZMB, IL10, IL11, IL15
43	hypereosinophilic syndrome	32.2	KIT, JUN, JAK2, CD69, AR, FGFR1
44	acute lymphocytic leukemia	32.2	RB1, VEGFA, MYC, BIRC5, BCL2, BCR
45	thrombocytosis	32.2	KITLG, SELP, SERPINF2, VEGFA, CEBPB, JAK1
46	non-hodgkin lymphoma	32.1	PIK3CA, PDCD1, KIR2DS5, KITLG, KIR3DL1, PCNA
47	juvenile myelomonocytic leukemia	32.1	KIR3DL1, BRAF, RAF1, JAK2, FLT3, INPP5D
48	acute promyelocytic leukemia	32.0	PIK3CG, NCAM1, MYC, BLZF1, BCL2, BAX
49	myelomonocytic leukemia	31.9	KIR3DL1, RB1, BRAF, MYC, MYB, RAF1
50	splenomegaly	31.9	VEGFA, JAK2, ITK, IL10, FASLG, FAS

Clinical features from OMIM: 608232

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 busulfan, cyclophosphamide, cytarabine, cytarabine liposome, doxorubicin hydrochloride, hydroxyurea, idarubicin, idarubicin hydrochloride, interferon alfa-2b, irinotecan, irinotecan hydrochloride, isotretinoin, methotrexate, methotrexate sodium, pipobroman, plicamycin, thioguanine, uracil mustard, vincristine, vincristine sulfate

Cell-based therapeutics:

MalaCards organs/tissues related to chronic myeloid leukemia:

²²

MGI Mouse Phenotypes related to chronic myeloid leukemia:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system phenotype	MP:0005397	16.2	PIAS4, PDCD1, KIT, SFRP1, PCNA, SERPINB2
2	mortality/aging	MP:0010768	15.4	PIK3CB, PIK3CA, PIAS4, NCAM1, PDCD1, RELA
3	immune system phenotype	MP:0005387	15.3	PIK3CD, PIAS4, PIK3R5, NCOA3, KIT, SFRP1
4	cellular phenotype	MP:0005384	13.9	PIK3CB, PIK3CD, PIK3CA, PIK3R1, PIK3R5, PIK3CG
5	nervous system phenotype	MP:0003631	13.5	PDCD1, RELA, KIT, KITLG, SFRP1, PCNT
6	growth/size phenotype	MP:0005378	13.0	PIK3CB, PIK3CA, PIK3R1, PIK3CG, NCOA3, RELA
7	integument phenotype	MP:0010771	12.7	PIK3CG, NCOA3, RELA, KIT, KITLG, RB1
8	behavior/neurological phenotype	MP:0005386	12.6	PIK3CA, NCAM1, NCOA3, KIT, PCNT, RB1
9	normal phenotype	MP:0002873	12.5	PIK3R1, RELA, BRAF, BRCA1, VEGFA, MYC
10	embryogenesis phenotype	MP:0005380	12.5	PIK3CB, PIK3CA, NCOA3, KIT, SFRP1, PCNT
11	craniofacial phenotype	MP:0005382	12.2	NCOA3, KIT, KITLG, BMI1, RAD23B, LIG3
12	endocrine/exocrine gland phenotype	MP:0005379	11.8	SELL, BRCA1, RAD23B, BCL2L2, LHX1, XPA
13	digestive/alimentary phenotype	MP:0005381	11.6	NCOA3, KIT, KITLG, RB1, BRAF, BRCA1
14	respiratory system phenotype	MP:0005388	11.5	SELL, SELP, BRCA1, PARK2, BCL6, FOXD3
15	homeostasis/metabolism phenotype	MP:0005376	11.3	PIK3CB, PIK3CD, PIK3CA, PIK3R2, PIK3R1, PIK3CG
16	limbs/digits/tail phenotype	MP:0005371	11.2	RELA, KIT, KITLG, SFRP1, PCNT, RB1
17	renal/urinary system phenotype	MP:0005367	11.0	NCOA3, PDCD1, KIT, SELP, BRAF, BRCA1
18	liver/biliary system phenotype	MP:0005370	10.8	NCOA3, KIT, VEGFA, MYB, LIG1, BCL6
19	cardiovascular system phenotype	MP:0005385	10.4	PIK3CB, PIK3CD, PIK3CA, PIK3R2, PIK3R1, PIK3CG
20	reproductive system phenotype	MP:0005389	10.3	PIK3CA, NCOA3, BRCA1, VEGFA, VDR, RAD23B
21	no phenotypic analysis	MP:0003012	10.1	PIK3CD, PIK3R1, SFRP1, PCNA, RB1, VEGFA
22	pigmentation phenotype	MP:0001186	10.0	KIT, KITLG, RB1, BRAF, BRCA1, MYC
23	tumorigenesis	MP:0002006	10.0	PIK3CB, PIK3CA, PIK3R2, PIK3R1, NCOA3, KIT
24	hearing/vestibular/ear phenotype	MP:0005377	9.9	NCOA3, KIT, KITLG, RB1, VDR, MYC
25	vision/eye phenotype	MP:0005391	9.6	PIK3CA, NCAM1, PDCD1, RELA, KIT, KITLG
26	skeleton phenotype	MP:0005390	9.4	PIK3CD, PIK3CG, RELA, KIT, KITLG, SFRP1
27	adipose tissue phenotype	MP:0005375	7.6	PIK3CA, PIK3R1, NCOA3, SFRP1, RB1, BRAF
28	muscle phenotype	MP:0005369	7.2	PIK3CA, PIK3R2, PIK3R1, PIK3CG, NCOA3, PDCD1

Articles related to chronic myeloid leukemia:

(show top 50)    (show all 575)

id	Title	Authors	Year	Affiliating Genes
1	Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nil otinib. (21762985)	Soverini S.... Martinelli G.	2011	BCR
2	Pharmacokinetic impact of SLCO1A2 polymorphisms on im atinib disposition in patients with chronic myeloid leukemia. (21633340)	Yamakawa Y.... Saito H.	2011	SLCO1A2
3	High STAT5 levels mediate imatinib resistance and ind icate disease progression in chronic myeloid leukemia. (21220747)	Warsch W.... Sexl V.	2011	STAT5A
4	Analysis of ABL kinase domain mutations conferring re sistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from I ndia. (21888027)	Bagadi S.... Das B.	2011	ABL1
5	Quantitative phosphoproteomics revealed interplay bet ween Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cel ls. (21730355)	Gioia R.... Pasquet J.M.	2011	SYK, LYN
6	Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. (21039054)	Sailaja K.... Vishnupriya S.	2010	CYP3A5
7	Analysis of BCR-ABL1 tyrosine kinase domain mutationa l spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. (20739956)	Grant H.... Woolfson A.	2010	BCR
8	Expression of the leukemic prognostic marker CD7 is l inked to epigenetic modifications in chronic myeloid leukemia. (20175919)	Rogers S.L.... Rouhi A.	2010	CD7, ELANE
9	Dasatinib in chronic myeloid leukemia: a review. (19536317)	Aguilera D.G.... Tsimberidou A.M.	2009	TKT
10	C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. (19039816)	Santucci M.A.... Botta M.	2009	IL3
11	BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. (18781299)	Bhattacharyya J.... Kimura A.	2009	BMI1
12	Simultaneous occurrence of variant Philadelphia trans locations and ABL mutations in two patients with chronic myeloid leukemia. (19203793)	Zhao Y.... Huang H.	2009	ABL1
13	JNK1/c-Jun and p38 alpha MAPK/ATF-2 pathways are resp onsible for upregulation of Fas/FasL in human chronic myeloid leukemia K562 cel ls upon exposure to Taiwan cobra phospholipase A2. (19670268)	Chen K.C.... Chang L.S.	2009	FAS, PLA2G6, FASLG
14	Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. (18406870)	Richebourg S.... Roche-Lestienne C.	2008	ABL1, BCR
15	Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. (18082628)	Gupta M.... Barbany G.	2008	ABL1, BCR
16	Overexpression of CHIP in chronic myeloid leukemia K562 cells induces mitotic abnormality (18718056)	Gao Y.... Yu X.D.	2008	STUB1
17	Overcoming kinase resistance in chronic myeloid leukemia. (18401881)	Lee F.... Voi M.	2008	HCK
18	Targeted chronic myeloid leukemia therapy: seeking a cure. (17970609)	Fausel C.	2007	BCR
19	Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. (16797705)	Bussolari R.... Calabretta B.	2007	MYB
20	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. (17284533)	Venturini L.... Scherr M.	2007	MIR17
21	The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. (17360938)	Mohty M.... Melo J.V.	2007	BMI1
22	Gene expression changes associated with progression and response in chronic myeloid leukemia. (16477019)	Radich J.P.... Linsley P.S.	2006	PRAME
23	Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl. (16443220)	Gutierrez-Berzal J.... Guerrero C.	2006	ABL1
24	Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. (16533530)	Cividin M.... Brizard A.	2006	CDKN2A, IFNA1
25	Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia (16255985)	Zhu X.Z.... Xu R.Z.	2005	ABL1, PTPN11
26	Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia. (15990995)	Anand M.... Sharma A.	2005	MPO
27	Differential molecular response of the transcripts B2 A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. (16475128)	de Lemos J.A.... Maradei-Pereira L.M.	2005	BLZF1
28	Identification of exocytosis mediator proteins in peripheral blood neutrophils of patients with chronic myeloid leukemia. (15452602)	Nuyanzina V.A.... Nabokina S.M.	2004	STX4, STX6
29	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. (12783374)	Cilloni D.... Saglio G.	2003	WT1
30	Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia. (12591277)	Tornhamre S.... Lindgren J.A.	2003	LTC4S
31	Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. (12463598)	Muta T.... Yamano Y.	2002	CALCA, PTHLH
32	BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. (12351420)	Gorre M.E.... Sawyers C.L.	2002	HSP90AA1
33	Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. (12130516)	Roche-Lestienne C.... Preudhomme C.	2002	ABL1
34	Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. (12225794)	Greiner J.... Schmitt M.	2002	HMMR
35	Interferon alpha plus intermittent oral Ara-C ocfosfa te (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cyt ogenetic response to interferon. (11726320)	Cervantes F.... Montserrat E.	2001	IFNA1
36	Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. (11013272)	Schmidt M.... Neubauer A.	2000	IRF4, IFNA1
37	Insertion of the 5' part of BCR within the ABL gene at 9q34 in a Philadelphia-negative chronic myeloid leukemia. (10526530)	Vieira L.... Boavida M.G.	1999	ABL1, BCR
38	Human phenylalanyl-tRNA synthetase: cloning, characterization of the deduced amino acid sequences in terms of the structural domains and coordinately regulated expression of the alpha and beta subunits in chronic myeloid leukemia cells. (10049785)	Rodova M.... Safro M.G.	1999	FARSA, FARSB
39	Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation (10028846)	Katagiri T.... Toyama K.	1998	CSF3
40	Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. (9716581)		1998	IFNA1
41	Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia. (9241616)	Russo D.... Grattoni R.	1997	IFNA1
42	Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. (9362160)		1997	IFNA1
43	Chronic myeloid leukemia (8629268)	Hehlmann R.	1996	IFNA1
44	Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy. (9042664)	Straetmans N.... Arthur C.	1996	IFNA1
45	Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: a cytochemical and immunohistochemical study of trephine biopsies. (8697144)	Thiele J.... Fischer R.	1996	IFNA1
46	Leukemic burden in subpopulations of CD34+ cells isol ated from the mobilized peripheral blood of alpha-interferon-resistant or -into lerant patients with chronic myeloid leukemia. (8639795)	Van Den Berg D.... Reading C.	1996	THY1
47	Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. (8652857)	Hasford J.... Zuffa E.	1996	IFNA1
48	Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. (8769707)	Aulitzky W.E.... Huhn D.	1996	IL3, CSF3
49	Effect of retinoic acid and interferon alpha on granu locyte-macrophage colony forming cells in chronic myeloid leukemia: increased i nhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease. (7934131)	Sagayadan G.E.... Gallagher R.E.	1994	IFNA2
50	Treatment of Ph-positive chronic myeloid leukemia with alpha-interferon (ROFERON-A). The Italian Cooperative Study Group experience. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. (8251889)		1993	IFNA2, IFNA1

Genes related to chronic myeloid leukemia according to GeneCards:

(show top 50)    (show all 412)

id	Symbol	Description	Score	GeneCards Section Context
1	ABL1	c-abl oncogene 1, non-receptor tyrosine kinase	11.1	Summaries, Pathways & Interactions, Functions, Orthologs (show all 5 sections) Publications
2	PCM1	pericentriolar material 1	11.1	Summaries
3	BCR	breakpoint cluster region	11.0	Publications, Pathways & Interactions
4	MIR219-2	microRNA 219-2	11.0	Publications
5	MIR150	microRNA 150	11.0	Publications
6	MIR451A	microRNA 451a	11.0	Publications
7	MIR199B	microRNA 199b	11.0	Publications
8	MIR10A	microRNA 10a	11.0	Publications
9	FAM27L	family with sequence similarity 27-like	11.0	Publications
10	HOXA@	homeobox A cluster	11.0	Publications
11	FBXO27	F-box protein 27	11.0	Publications
12	MIR17	microRNA 17	11.0	Publications
13	FOXD3	forkhead box D3	11.0	Expressions
14	ULK3	unc-51-like kinase 3 (C. elegans)	11.0	Publications
15	IFNA1	interferon, alpha 1	11.0	Publications
16	CEACAM8	carcinoembryonic antigen-related cell adhesion molecule 8	11.0	Publications, Expressions
17	PRAME	preferentially expressed antigen in melanoma	11.0	Publications
18	SLC22A1	solute carrier family 22 (organic cation transporter), member 1	11.0	Publications
19	IFN1@	interferon, type 1, cluster	11.0	Publications
20	C6orf211	chromosome 6 open reading frame 211	11.0	Publications
21	TMEM37	transmembrane protein 37	11.0	Publications
22	DDX43	DEAD (Asp-Glu-Ala-Asp) box polypeptide 43	11.0	Publications
23	BMI1	BMI1 polycomb ring finger oncogene	11.0	Publications
24	IFITM1	interferon induced transmembrane protein 1	11.0	Publications
25	CD52	CD52 molecule	11.0	Publications
26	LHX1	LIM homeobox 1	11.0	Expressions
27	CEACAM4	carcinoembryonic antigen-related cell adhesion molecule 4	11.0	Publications
28	PRDM12	PR domain containing 12	11.0
29	FARSA	phenylalanyl-tRNA synthetase, alpha subunit	11.0	Publications
30	RIN1	Ras and Rab interactor 1	11.0	Publications
31	HOXA9	homeobox A9	11.0	Publications
32	ID4	inhibitor of DNA binding 4, dominant negative helix-loop-helix protein	11.0	Publications
33	ORM1	orosomucoid 1	11.0	Publications
34	ORM2	orosomucoid 2	11.0	Publications
35	P2RX5	purinergic receptor P2X, ligand-gated ion channel, 5	11.0	Publications
36	ULBP2	UL16 binding protein 2	11.0	Publications
37	MEPCE	methylphosphate capping enzyme	11.0	Expressions
38	CRKL	v-crk sarcoma virus CT10 oncogene homolog (avian)-like	11.0	Publications, Pathways & Interactions
39	KIR2DS5	killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5	11.0	Publications
40	SOCS2	suppressor of cytokine signaling 2	11.0	Publications
41	HDGF	hepatoma-derived growth factor	11.0	Publications
42	ZBTB2	zinc finger and BTB domain containing 2	11.0	Publications
43	OSBP	oxysterol binding protein	11.0	Publications
44	VAMP7	vesicle-associated membrane protein 7	11.0	Publications
45	WSB1	WD repeat and SOCS box containing 1	11.0	Publications
46	CD7	CD7 molecule	11.0	Publications
47	CBLC	Cbl proto-oncogene, E3 ubiquitin protein ligase C	11.0	Pathways & Interactions
48	TDRKH	tudor and KH domain containing	11.0	Publications
49	CIDEA	cell death-inducing DFFA-like effector a	11.0	Publications
50	BCL2L2	BCL2-like 2	11.0	Publications

Pathways related to chronic myeloid leukemia according to GeneDecks:

(show top 50)    (show all 537)

id	Pathway	Score	Top Affiliating Genes
1	Natural killer cell mediated cytotoxicity20	12.1	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
2	Jak/Stat Pathway3	11.3	PIAS4, JAK1, JAK2, IL1RN, PTPN6, TYK2
3	Immune response ICOS pathway in T-helper cell10	11.3	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
4	Translation Regulation activity of EIF4F10	11.3	PIK3CB, PIK3CD, PIK3R3, PIK3R2, AKT2, AKT3
5	Translation Insulin regulation of translation10	11.2	PIK3CB, PIK3CD, PIK3R3, PIK3R2, PIK3R1, RAF1
6	Signal transduction_IP3 signaling41	11.1	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, RAF1
7	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways37	11.1	PIK3CB, PIK3CD, PIK3R1, PIK3CG, BRAF, RAF1
8	Development Leptin signaling via PI3K-dependent pathway10	11.0	PIK3CB, PIK3CD, PIK3CA, PIK3R2, PIK3R1, CHUK
9	Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins41	11.0	RAF1, BCL2, BCL2L1, BCL2L11, BCL2L2, BBC3
10	Development Growth hormone signaling via PI3K/AKT and MAPK cascades10	11.0	PIK3CA, PIK3R1, RAF1, CEBPB, JUN, JUNB
11	Signal transduction_PTEN pathway41	10.9	PCNA, ITGB1, CASP9, TSC2
12	Paxillin Interactions36	10.8	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, KDR
13	Development_Alpha-2 adrenergic receptor activation of ERK41	10.8	PIK3R3, GRB2, GNB3, HRAS, SHC1, EGFR
14	IL-7 Signaling Pathways37	10.8	PIK3CB, PIK3CD, PIK3R1, PIK3CG, RAF1, BAD
15	Immune response IL-23 signaling pathway10	10.8	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
16	TCR Signaling36	10.8	PIK3R3, PIK3R2, PIK3R1, RAF1, CHUK, JUN
17	Development A1 receptor signaling10	10.7	PIK3R5, PIK3CG, RELA, RAF1, CHUK, GRB2
18	Development_Dopamine D2 receptor transactivation of EGFR41	10.7	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
19	Immune response CD28 signaling10	10.7	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
20	Translation Regulation activity of EIF210	10.7	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
21	Development_Angiotensin signaling via PYK241	10.7	PIK3R3, PIK3R2, PIK3R1, RAF1, JUN, GRB2
22	Cell adhesion_PLAU signaling41	10.6	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
23	LPS Stimulated MAPK Signaling36	10.6	PIK3R3, PIK3R2, PIK3R1, RAF1, CHUK, ATF1
24	Ceramide Pathway36	10.6	PIK3R3, PIK3R2, PIK3R1, RAF1, BAD, ATF1
25	Development A3 receptor signaling10	10.5	PIK3R5, PIK3CG, RELA, MYC, RAF1, CHUK
26	Development_A2B receptor- action via G-protein alpha s41	10.5	PIK3CB, PIK3CD, PIK3CA, RELA, BRAF, CEBPB
27	HGF Pathway36	10.5	PIK3R3, PIK3R2, PIK3R1, RB1, RAF1, JUN
28	Signal transduction_AKT signaling41	10.5	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
29	Measles20	10.4	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
30	T cell receptor signaling pathway20	10.4	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
31	Apoptosis and survival TNFR1 signaling pathway10	10.2	RELA, CHUK, BAX, XIAP, JUN, APAF1
32	JNK Pathway36	10.2	PIK3R1, KIT, KITLG, BMP6, RAF1, KDR
33	Immune response Oncostatin M signaling via MAPK in human cells10	10.1	RAF1, CEBPB, JUN, JUNB, JAK1, GRB2
34	TNF Signaling36	10.0	CHUK, ATF1, JUN, APAF1, MAPK8, MAPK3
35	Influenza A20	9.9	PIK3CB, PIK3CD, PIK3CA, PIK3R3, PIK3R2, PIK3R1
36	GSK3 Signaling36	9.9	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, BMP6
37	Cytokine production by Th17 cells in CF (Mouse model)41	9.8	RELA, CHUK, JAK2, IRF4, IL6, IL8
38	STAT3 Pathway36	9.8	BRAF, MYC, BMP6, RAF1, BCL2, BAX
39	Signaling Involved in Cardiac Hypertrophy36	9.8	PIK3R3, PIK3R2, PIK3R1, BRAF, RAF1, JUN
40	Tuberculosis20	9.7	RELA, VDR, RAF1, BCL2, BAD, BAX
41	Telomerase Components in Cell Signaling36	9.7	KIT, KITLG, RB1, MYC, BMP6, KDR
42	Phospholipase-C Pathway36	9.6	KIT, KITLG, BMP6, RAF1, KDR, ITGAE
43	JAK-STAT Pathway36	9.5	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, BRCA1
44	Cellular Apoptosis Pathway36	9.5	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, BMP6
45	Pancreatic Adenocarcinoma36	9.5	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, RB1
46	MAPK signaling pathway20	9.4	RELA, BRAF, MYC, RAF1, CHUK, JUN
47	MAPK Signaling36	9.3	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, BRAF
48	NOD-like receptor signaling pathway20	9.1	RELA, CHUK, XIAP, IL18, IL1B, IL6
49	Estrogen Pathway36	8.8	PIK3R3, PIK3R2, PIK3R1, NCOA3, KIT, KITLG
50	Rho Family GTPases36	8.6	PIK3R3, PIK3R2, PIK3R1, KIT, KITLG, BMP6

Compounds related to chronic myeloid leukemia according to GeneDecks:

(show top 50)    (show all 378)

id	Compound	Score	Top Affiliating Genes
1	calcium32 9 18 9	17.7	PIK3CD, RELA, KIT, KITLG, RB1, SERPINF2
2	lipid32	13.3	PIK3CB, PIK3CD, PIK3CA, PIK3R1, PIK3CG, NCAM1
3	glucose32	12.5	KIT, BRAF, PARK2, CHUK, BAD, XIAP
4	adp32 18	12.7	PIK3CB, PIK3CD, PIK3CA, PIK3CG, KIT, SELP
5	phosphotyrosine32	11.6	PIK3CB, PIK3CA, PIK3R1, PIK3CG, KIT, KIR3DL1
6	nitric oxide32 9 18 9	14.1	PIK3CB, NCAM1, KIT, KITLG, RB1, SELP
7	estrogen32	11.0	ZNF673, PIK3CB, PIK3R1, NCOA3, PCNA, SERPINB2
8	dasatinib32 34 9 9	14.0	KIT, BCL2L1, BCR, MCL1, PTK2, CYP1A1
9	retinoic acid32 42 18	13.0	PIK3CA, PIK3CG, NCAM1, NCOA3, KIT, KITLG
10	hydroxyurea32 9 9	13.0	KIT, KITLG, PCNA, SELL, BRCA1, MYC
11	ascorbic acid32 18	11.9	PIK3CG, PCNA, SERPINB2, VDR, RAF1, CHUK
12	vinblastine32 9 9	12.9	RAF1, BIRC5, KDR, BCL2, BCL2L1, BAX
13	n-formylmethionyl-leucylphenylalanine32	10.8	PIK3CG, SELL, SELP, LCN2, MPO, CD55
14	daunorubicin32 9 9	12.8	RELA, KITLG, MYC, RAF1, BIRC5, BCL2
15	hoechst 3334232	10.8	KITLG, PCNA, BIRC5, PARP1, BCL2, BAX
16	dutp32	10.7	PCNA, BIRC5, PARP1, BCL2, BCL2L1, BAX
17	zidovudine32 9 9	12.6	KITLG, MYC, IL10, IL3, CCL3, IFNA1
18	norepinephrine32 9 18 9	13.5	KITLG, SELL, SELP, BMP6, LEP, ATF1
19	aspirin32 34 18	12.5	KITLG, PCNA, SELL, SELP, VDR, BMP6
20	isoproterenol32 9 9	12.5	PIK3R3, PIK3R2, PIK3R1, SELL, BRAF, RAF1
21	depsipeptide32	10.4	KITLG, RB1, BRAF, MYC, RAF1, BCL2
22	z-vad-fmk32 42	11.3	PARP1, BCL2, BCL2L1, BAX, GZMB, MAPK14
23	progesterone32 42 9 18 9	14.3	PIK3CA, PIK3R1, NCAM1, NCOA3, KIT, PCNA
24	sulfasalazine32 9 9	12.3	CHUK, MPO, IL1A, IL1B, IL1R1, IL1RN
25	gtp32	10.2	PIK3CA, PIK3R1, BRAF, RAF1, RAN, BLZF1
26	betulinic acid32	10.2	BIRC5, PARP1, BCL2, BCL2L1, MCL1, FASLG
27	calcitriol32 42 9 18 9	14.2	PIK3CB, NCOA3, KITLG, RB1, VDR, MYC
28	arsenite32 18	11.1	PIK3CA, PIK3R1, PIK3CG, PCNA, VEGFA, VDR
29	arachidonic acid32 9 18 9	13.0	PIK3CA, NCAM1, KITLG, SELP, BCL2L1, JUNB
30	sulforaphane32	10.0	PIK3CG, RB1, PARP1, JUN, CDKN1A, CDC25C
31	cd 43732	9.9	MYC, PARP1, BCL2, BCL2L1, BAX, JUN
32	c2ceramide32	9.9	PIK3CG, PARP1, BCL2L1, CHUK, UGCG, BAX
33	adpribose32	9.8	PIK3CA, PIK3CG, PCNA, RB1, BRCA1, LIG3
34	glutamine32	9.7	PIK3CG, NCAM1, NCOA3, KIT, PCNA, SERPINF2
35	mifepristone32 42 9 9	12.7	BIRC5, BCL2L1, BAX, JUN, JAK1, CDK2
36	butyrate32	9.6	NCOA3, KITLG, PCNA, RB1, VDR, MYC
37	nocodazole32 42 9 9	12.4	PCNT, BRCA1, RAF1, RAN, BIRC5, CDKN1A
38	dihydrotestosterone32 9 18 9	12.4	NCOA3, VDR, BMP6, LEP, CDK6, CDK2
39	suberoylanilide hydroxamic acid32	9.4	MYC, RAF1, BIRC5, PARP1, BCL2, BCL2L1
40	simvastatin32 34 42 9 18 9	14.3	KITLG, SELL, SELP, VEGFA, BMP6, KDR
41	thymidine32 18	10.3	PIK3CA, PIK3R1, KIT, KITLG, PCNA, RB1
42	creatinine32	9.3	NCAM1, KITLG, PCNA, SELL, SELP, VDR
43	anisomycin32 42 9 9	12.2	PIK3CG, MYC, RAF1, JUN, JUNB, CDC42
44	indole-3-carbinol32	9.2	BRCA1, BIRC5, PARP1, BCL2, BCL2L1, BAX
45	rosiglitazone32 9 18 9	12.1	PIK3CA, PIK3CG, LEP, LCN2, JUN, JAK2
46	herbimycin a32 42	10.0	PIK3CG, KITLG, SELL, MYC, BMP6, RAF1
47	geldanamycin32 9 9	10.8	PIK3R1, PIK3CG, BRAF, VEGFA, RAF1, BIRC5
48	tamoxifen32 34 9 9	11.8	PIK3CA, NCOA3, PCNA, BRCA1, VEGFA, VDR
49	pd 98,05932	8.6	PIK3CA, PIK3R1, PIK3CG, KIT, KITLG, RB1
50	paraffin32	8.6	NCAM1, RELA, KIT, KITLG, PCNA, RB1

Cellular components related to chronic myeloid leukemia according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:005737	14.2	BRAF, PIAS4, PIK3R5, PIK3CG, SERPINB2, SELP
2	nucleus	GO:005634	13.6	GFI1B, RPA1, PLK1, CRY2, CRK, SMARCB1
3	cytosol	GO:005829	13.3	GAB2, HDAC1, ADA, LYN, NME1, PML
4	plasma membrane	GO:005886	13.2	INPP5D, CD59, CDC42, CEACAM6, CEACAM8, UBC
5	integral to plasma membrane	GO:005887	12.2	TNF, HLA-DRB4, HLA-DPA1, ICAM1, IFNGR2, IFNGR1
6	transcription factor complex	GO:005667	11.0	SMAD3, SMAD4, GFI1B, POU5F1, POU2F1, HDAC9
7	nucleoplasm	GO:005654	10.7	E2F3, E2F2, E2F1, HDGF, HDAC3, HDAC2
8	external side of plasma membrane	GO:009897	10.5	ADA, IL4, ITGB1, ITGAE, CD44, CD83
9	cell surface	GO:009986	10.0	TGFA, ELANE, ABCB1, PLAU, CR1, TGFB1
10	extracellular space	GO:005615	8.3	ICAM1, IL1RN, IL1B, IL1A, IL18, IL15

Biological processes related to chronic myeloid leukemia according to GeneDecks:

(show top 50)    (show all 91)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein phosphorylation	GO:006468	12.1	PIK3CD, BRAF, RAF1, BIRC5, BCR, CHUK
2	peptidyl-tyrosine phosphorylation	GO:018108	11.8	KIT, KDR, JAK1, JAK2, FLT3, FGFR1
3	apoptotic process	GO:006915	11.6	PDCD1, PCNT, BRCA1, RAF1, BIRC5, BCL2
4	induction of apoptosis	GO:006917	11.5	BCL2L11, BBC3, BAD, BAX, CEBPB, CDKN1B
5	cytokine-mediated signaling pathway	GO:019221	11.3	NCAM1, RELA, KIT, UBC, BAD, JAK1
6	interferon-gamma-mediated signaling pathway	GO:060333	11.3	NCAM1, JAK1, JAK2, CD44, IRF4, IRF8
7	insulin receptor signaling pathway	GO:008286	11.2	PIK3CB, PIK3CA, PIK3R3, PIK3R2, PIK3R1, RAF1
8	leukocyte migration	GO:050900	11.1	PIK3CB, PIK3CA, PIK3R2, PIK3R1, SELL, SELP
9	induction of apoptosis by intracellular signals	GO:008629	11.1	MYC, BCL2, BCL2L1, BCL2L11, BBC3, BAD
10	blood coagulation	GO:007596	11.0	PIK3CB, PIK3CA, PIK3R3, PIK3R2, PIK3R1, PIK3R5
11	activation of pro-apoptotic gene products	GO:008633	11.0	MYC, BCL2, BCL2L11, BBC3, BAD, BAX
12	signal transduction	GO:007165	11.0	PIK3CB, PIK3CD, PDCD1, KIT, KITLG, VDR
13	T cell receptor signaling pathway	GO:050852	11.0	PIK3CB, PIK3CD, PIK3CA, PIK3R2, PIK3R1, RELA
14	positive regulation of cell proliferation	GO:008284	11.0	KIT, SFRP1, VEGFA, MYC, BIRC5, KDR
15	negative regulation of transcription from RNA polymerase II promoter	GO:000122	10.9	PIAS4, VDR, MYC, MYB, BMI1, PARP1
16	positive regulation of gene expression	GO:010628	10.9	NCOA3, KIT, BRAF, VEGFA, VDR, LEF1
17	innate immune response	GO:045087	10.8	PIK3CD, PIK3CG, RELA, VNN1, BCL2, BCL2L1
18	fibroblast growth factor receptor signaling pathway	GO:008543	10.7	PIK3CA, PIK3R1, BRAF, RAF1, CHUK, UBC
19	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.7	KIT, CDC42, FLT3, FGF2, FGFR3, FGR
20	positive regulation of cell migration	GO:030335	10.6	VEGFA, KDR, LEF1, JAK2, CDH13, ITGB1
21	Ras protein signal transduction	GO:007265	10.6	RB1, RAF1, RASSF1, CDKN1A, CDK2, CDKN2A
22	nerve growth factor receptor signaling pathway	GO:048011	10.6	PIK3CB, PIK3CA, PIK3R2, PIK3R1, RELA, BRAF
23	negative regulation of transcription, DNA-dependent	GO:045892	10.5	PIAS4, RELA, SFRP1, RB1, BRCA1, VDR
24	response to organic cyclic compound	GO:014070	10.5	SFRP1, SELP, LEF1, ATF1, JUN, JUNB
25	toll-like receptor signaling pathway	GO:002224	10.5	RELA, CHUK, UBC, ATF1, JUN, CDK1
26	MyD88-dependent toll-like receptor signaling pathway	GO:002755	10.5	RELA, CHUK, UBC, ATF1, JUN, CDK1
27	MyD88-independent toll-like receptor signaling pathway	GO:002756	10.5	RELA, CHUK, UBC, ATF1, JUN, CDK1
28	virus-host interaction	GO:019048	10.4	PIK3R1, RELA, RB1, RAN, KDR, BAX
29	toll-like receptor 1 signaling pathway	GO:034130	10.4	RELA, CHUK, UBC, ATF1, JUN, CDK1
30	toll-like receptor 2 signaling pathway	GO:034134	10.4	RELA, CHUK, UBC, ATF1, JUN, CDK1
31	toll-like receptor 3 signaling pathway	GO:034138	10.4	RELA, CHUK, UBC, ATF1, JUN, CDK1
32	TRIF-dependent toll-like receptor signaling pathway	GO:035666	10.4	RELA, CHUK, UBC, ATF1, JUN, CDK1
33	activation of MAPK activity	GO:000187	10.4	PIK3CB, KIT, UBC, CDK1, FPR1, FGF2
34	activation of MAPKK activity	GO:000186	10.4	RAF1, JAK2, MAP2K2, NRAS, CRK
35	epidermal growth factor receptor signaling pathway	GO:007173	10.4	PIK3CA, PIK3R1, RAF1, CHUK, UBC, BAD
36	positive regulation of DNA replication	GO:045740	10.4	KITLG, ATF1, JUN, CDC42, CDK1, MET
37	Toll signaling pathway	GO:008063	10.3	RELA, CHUK, UBC, ATF1, JUN, CDK1
38	toll-like receptor 4 signaling pathway	GO:034142	10.3	RELA, CHUK, UBC, ATF1, JUN, CDK1
39	anti-apoptosis	GO:006916	10.2	PIK3CA, RELA, SERPINB2, VNN1, BRAF, BIRC5
40	phosphatidylinositol-mediated signaling	GO:048015	10.1	PIK3CB, PIK3CA, PIK3R2, PIK3R1, PCNA, CHUK
41	response to drug	GO:042493	10.0	SFRP1, MYC, BCL2, JUN, JUNB, CDKN1A
42	MAPK cascade	GO:000165	10.0	MYC, RAF1, CDK1, FGFR1, FGFR3, IL18
43	platelet activation	GO:030168	9.8	PIK3CB, PIK3CA, PIK3R3, PIK3R2, PIK3R1, PIK3R5
44	inflammatory response	GO:006954	9.7	PIK3CD, PIK3CG, RELA, KIT, SELP, VNN1
45	cell cycle arrest	GO:007050	9.7	RB1, MYC, RASSF1, CDK6, CDKN1A, CDKN2B
46	negative regulation of apoptotic process	GO:043066	9.3	PIK3CG, RELA, SFRP1, BRAF, VEGFA, MYC
47	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.3	PIK3CA, BRAF, VEGFA, RAF1, BCL2, CDC42
48	positive regulation of transcription, DNA-dependent	GO:045893	9.3	NCOA3, RELA, SFRP1, RB1, BRCA1, MYC
49	negative regulation of cell proliferation	GO:008285	9.2	SFRP1, VDR, RAF1, BCL6, JUN, JAK2
50	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.1	NCOA3, RELA, RB1, SERPINF2, BRCA1, VEGFA

Molecular functions related to chronic myeloid leukemia according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:005515	16.2	TGFB2, PRDM16, PRAME, PRTN3, PRDX3, SOCS1
2	ATP binding	GO:005524	12.6	PIK3CG, CDK2, CDK4, CDK1, ITK, MLH1
3	sequence-specific DNA binding transcription factor activity	GO:003700	11.7	STAT1, STAT5A, STAT3, WT1, NFKB1, SMAD4
4	non-membrane spanning protein tyrosine kinase activity	GO:004715	11.6	ABL1, ABL2, HCK, TYK2, SYK, LYN
5	protein tyrosine kinase activity	GO:004713	11.4	MAP2K1, PTK2B, SRC, PDGFRB, SHC1, EGFR
6	protein kinase binding	GO:019901	11.2	SOCS1, RELA, PARK2, BCL2L1, BAD, JAK2
7	protein homodimerization activity	GO:042803	10.9	TSC2, TWIST1, ABCG2, PDGFRA, NFKB1, SMAD4
8	phosphotyrosine binding	GO:001784	10.8	PTPN6, CBLC, CBLB, CBL, MAPK3, GRB2
9	protein kinase activity	GO:004672	10.7	AKT1, AKT3, ERCC2, PTK2, DAPK1, SRC
10	transcription factor binding	GO:008134	10.6	CTBP1, CTNNB1, SMAD3, NFKBIA, TWIST1, STAT3
11	protein heterodimerization activity	GO:046982	10.2	LTC4S, TP53, IKBKB, MCL1, MET, EGFR
12	identical protein binding	GO:042802	9.9	SMAD4, TNF, TP53, ESR1, AKT1, NFKBIA
13	cytokine activity	GO:005125	9.7	IL6, FASLG, IFNA2, IFNG, TNF, TGFB2
14	enzyme binding	GO:019899	9.5	NFKBIA, EGFR, TGFB1, STAT1, STUB1, PRTN3
15	transcription regulatory region DNA binding	GO:044212	9.4	SMAD4, NFKB1, WT1, STAT3, POU5F1, WNT1
16	growth factor activity	GO:008083	9.2	TGFA, TGFB1, TGFB2, TGFB3, CXCL12, CSF1